Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.53 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1E | P28566 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11264196 | 0.95 | CYP2D6 (0.49) | HTR2AHTR2CHTR2BHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL11269391 | 0.93 | CYP2D6 (0.47) | HTR2AHTR2CHTR2BHTR1AHTR1D | |
| SCHEMBL10401509 | 0.91 | HTR2C (0.56) | HTR2AHTR2CHTR2BHTR1AHTR1D | |
| SCHEMBL2863498 | 0.83 | HTR2C (0.69) | HTR2AHTR2C | |
| SCHEMBL567956 | 0.83 | HTR2C (0.69) | HTR2AHTR2C | |
| SCHEMBL3037448 | 0.83 | HTR2C (0.69) | HTR2AHTR2C | |
| SCHEMBL29064016 | 0.83 | ALDH1A1 (0.48) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL567518 | 0.82 | HTR2C (0.70) | HTR2AHTR2C | |
| SCHEMBL2145393 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR6 | |
| SCHEMBL28301764 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| CN-104703970-A | Substituted carbamate compounds and their use as transient receptor potential (TRP) channel antagonists | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| WO-2014060341-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| EP-0062018-A1 | Novel phenyl-piperidines | Aktiebolaget Hässle (SE) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218141-A1 | SUBSTITUTED CARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | HTR2A 793/4885HTR2C 819/4885HTR2B 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.